Event Details
ESTRO 2021
Aug 27 2021
At this year's Annual Meeting of the European Society for Radiotherapy and Oncology (ESTRO), Nanobiotix will be providing encore presentations of updated data from its phase I head and neck cancer study, phase I immunotherapy study and phase III soft tissue sarcoma study.
Founded in 1980, ESTRO is a non-profit scientific organization that aims to further reinforce radiation oncology as a core partner in multidisciplinary cancer care and to guarantee accessible and high-value radiation therapy for all cancer patients who need it. The congress will take place in Madrid, Spain from August 27 to 31 and the entire program will be available online as well.
Agenda
Abstract Number: E21-0764
Abstract Title: NBTXR3 activated by SBRT combined with nivolumab or pembrolizumab in advanced cancers: phase I trial.
Presenter: Dr. Colette Shen
Presentation Date: 28 August 2021, 8.45 - 9.45 am (CEST) - Poster presentation online
Clinical session: Poster Highlights 2: Head and neck 1
Abstract Number: E21-0882
Abstract Title: Long-term results from the phase II/III Act.In.Sarc trial evaluating NBTXR3 in locally advanced STS
Presenter: Pr. Sylvie Bonvalot
Presentation Date: 28 August 2021, 4.45 - 5.45 pm (CEST) - Oral presentation online
Clinical session: Proffered papers 13: Haematology / Paediatrics / Sarcoma
Abstract Number: E21-0823
Abstract Title: NBTXR3 activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients
Presenter: Pr. Christophe Le Tourneau
Presentation Date: 30 August 2021, 10.30 - 11.30 am (CEST) - Oral presentation on-site
Clinical session: Proffered papers 31: Head and neck